Longwood Fund

Longwood Fund, founded in 2010 and based in Boston, Massachusetts, is a venture capital firm specializing in creating and investing in science-based companies that develop novel solutions to address important medical needs. The fund's principals have co-founded 25 companies, serving as CEOs, Chief Business Officers, and lead investors, and have helped advance over 20 products to market. Longwood Fund's portfolio includes several notable companies such as Grail, which focuses on early cancer detection, and TScan Therapeutics, which develops novel T cell therapies for cancer. Other significant investments include Immunitas Therapeutics, a company using single-cell genomics to innovate in immune oncology, and Be Biopharma, which is developing engineered B cells as a new category of cellular medicines. The fund emphasizes a value-add investment approach, actively supporting its portfolio companies in accelerating clinical progress from lab to patient. With a strong track record of successful exits, including Pyxis Oncology and PTC Therapeutics, Longwood Fund continues to play a pivotal role in advancing healthcare innovations.